rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    CRSP
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      CRISPR Therapeutics (CRSP) Flags Early CTX310 And Zugo Cel Wins In Two Big Markets
      19h agoYahoo FinanceCRSP
      CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
      Nov 17Yahoo FinanceCRSP
      CRISPR Therapeutics Eyes Late-Stage Trials as Key Data and CASGEVY Demand Build
      Nov 17Yahoo FinanceCRSP
      InvestingPro Fair Value flagged CRISPR as overvalued before 47% drop By Investing.com
      Nov 17Investing.comCRSP
      CRISPR Therapeutics at Jefferies Global Healthcare Conference: pipeline deepens
      Nov 17Investing.comCRSP
      DNA drug developer Seawolf launches with $100 million funding, Sanofi deal
      Nov 16ReutersCRSPSNY
      Crispr Therapeutics stock hits 52-week low at $44.10
      Nov 12Investing.comCRSP
      Crispr Therapeutics: More Patients, Same Losses (NASDAQ:CRSP)
      Nov 12Seeking AlphaCRSP
      CRISPR Therapeutics AG (CRSP) Presents at AHA Scientific Sessions 2026 - Slideshow (NASDAQ:CRSP) 2026-11-11

      2026-11-11. The following slide deck was published by CRISPR Therapeutics AG in conjunction with this event.

      Nov 11Seeking AlphaCRSP
      Crispr: Recent Drop In Short Interest Indicates Deteriorating Bearish Sentiment (CRSP)

      Crispr Therapeutics is rated a Buy, citing a strong balance sheet, derisked pipeline, and favorable risk/reward ratio. Discover more on CRSP in this article.

      Nov 10Seeking AlphaCRSP
      CRISPR Therapeutics Highlights Substantial Lipid Reductions with Investigational Gene Editing Therapy
      Nov 10BenzingaCRSP
      CRISPR Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

      ZUG, Switzerland and BOSTON, Nov. 10, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior man...

      Nov 10Business InsiderCRSPJEF
      Piper Sandler reiterates CRISPR Therapeutics stock rating at overweight
      Nov 10Investing.comCRSP
      CRISPR Therapeutics: I Love The Medical Breakthroughs, I Don't Love The Stock - Strong Sell
      Nov 9Seeking AlphaCRSP
      CRISPR Therapeutics reports trial results for gene therapy CTX310
      Nov 9Investing.comCRSP
      CRISPR Therapeutics Presents Phase 1b Data for CTX310® Demonstrating Reductions in ANGPTL3 and Triglycerides in Patients with Severe Hypertriglyceridemia at the American Heart Association (AHA) Scientific Sessions 2026
      Nov 9Yahoo FinanceCRSP
      CRISPR Therapeutics Provides Update on Zugocabtagene Geleucel (Zugo-cel) in Refractory Rheumatologic Autoimmune Diseases

      Systemic sclerosis (SSc) data presented at ACR Convergence 2026 showed 83% (5/6) of patients receiving standard lymphodepletion achieved a clinical response (rCRISS-25) at Month 3, with all responders maintaining response Zugo-cel has been well tolerated in all 21 patients dosed to date, with no cytokine release syndrome (CRS) above Grade 2 and no immune effector cell-associated neurotoxicity syndrome (ICANS) or immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IE

      Nov 8Yahoo FinanceCRSP
      CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It

      CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

      Nov 6Yahoo FinanceCRSP
      Crispr Therapeutics AG (CRSP) Receives a Hold from RBC Capital

      Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

      Nov 5The Globe and MailCRSP
      Wells Fargo cuts CRISPR Therapeutics stock price target on earnings
      Nov 4Investing.comCRSP
      CRISPR Therapeutics (CRSP) Stock Looks Fully Valued As It Names A New CTO
      Nov 3Yahoo FinanceCRSP
      CRISPR Therapeutics (CRSP) Appoints Siva Sakhamuri As Chief Technical Officer

      CRISPR Therapeutics (NasdaqGM:CRSP) appointed Siva Sakhamuri, Ph.D., as Chief Technical Officer, according to a recent company announcement. Dr. Sakhamuri brings experience leading technical operations and manufacturing functions at established biotechnology enterprises focused on complex biologics. His background includes work on gene editing and RNA based therapies as well as oversight of regulatory submissions and commercial launches. The appointment of Dr. Siva Sakhamuri as Chief...

      Nov 3Yahoo FinanceCRSP
      Crispr Therapeutics Reports Growing Casgevy Use Ahead of Key Pipeline Data, RBC Says
      Nov 3Yahoo FinanceCRSP
      CRSP's Q3 Loss Wider Than Expected, Sales Beat Estimates
      Nov 3Yahoo FinanceCRSP
      Citizens reiterates CRISPR Therapeutics stock rating on Casgevy sales
      Nov 3Investing.comCRSP
      CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Tops Revenue Estimates
      Nov 2Yahoo FinanceCRSP
      Crispr Therapeutics earnings missed by $0.11, revenue fell short of estimates
      Nov 2Investing.comCRSP
      CRISPR Therapeutics reports Q3 revenue of $99 million
      Nov 2Investing.comCRSP
      Casgevy Starts Paying Off for CRISPR: Rapid Earnings Reaction | The Motley Fool

      CRISPR's first approved therapy is gaining traction, but the company's finances still lean on its cash reserves and an expensive pipeline.

      Nov 2The Motley FoolCRSP
      CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results

      – CASGEVY® revenue of $99 million in the third quarter of 2026, up 30% quarter-over-quarter and nearly six times the third quarter of 2025 – – CASGEVY approved in the U.K. for children 5 years of age and older with severe SCD or TDT, and in the United Arab Emirates and Bahrain for children 2 years of age and older – – FDA granted Regenerative Medicine Advanced Therapy (RMAT) designations to CTX310® for severe hypertriglyceridemia and elevated LDL-C – – Phase 1b data for CTX310 in severe hypertri

      Nov 2Yahoo FinanceCRSP
      CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
      Nov 2Yahoo FinanceCRSP
      CRISPR Therapeutics names Sivakesava Sakhamuri as CTO
      Nov 2Investing.comCRSP
      CRISPR Therapeutics Announces the Appointment of Siva Sakhamuri, Ph.D., as Chief Technical Officer

      ZUG, Switzerland and BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), today announced the appointment of Sivakesava (Siva) Sakhamuri, Ph.D., as Chief Technical Officer, effective immediately. Dr. Sakhamuri brings about 30 years of technical operations and manufacturing leadership experience across biologics, vaccines, oligonucleotides, RNA therapeutics and lipid nanoparticle (LNP) delivery. “Siva has tremendous experience advancing novel therapies across various moda

      Nov 2Yahoo FinanceCRSP
      Here's Why CRISPR Therapeutics AG (CRSP) Fell More Than Broader Market
      Oct 30Yahoo FinanceCRSP
      Learn Why The Bull Case For CRISPR Therapeutics Stock Could Change Following CFO Change
      Oct 25Yahoo FinanceCRSP
      CRISPR Therapeutics (CRSP) Promotes Andrew Silver To CFO As Raju Prasad Resigns

      CRISPR Therapeutics (NasdaqGM:CRSP) has promoted Andrew J. Silver to Chief Financial Officer, effective October 19, 2026. Outgoing CFO Raju Prasad, Ph.D., has resigned from his role, also effective October 19, 2026. Silver steps into the finance chief role after serving within CRISPR Therapeutics, bringing internal experience to the transition. The CFO handover from Raju Prasad to Andrew J. Silver is only one piece of CRISPR Therapeutics' broader story today. Check out 2 other big wins that...

      Oct 25Yahoo FinanceCRSP
      Forget Casgevy: CRISPR Therapeutics' Heart-Disease Data Could Matter More | The Motley Fool

      The company's gene-editing-focused platform looks promising.

      Oct 24The Motley FoolCRSP
      CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know
      Oct 23Yahoo FinanceCRSP
      Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know
      Oct 23Yahoo FinanceCRSP
      The Outlook of CRISPR Therapeutics Stock Does Not Look Strong After Its CFO Resigns
      Oct 23Yahoo FinanceCRSP
      CRISPR Therapeutics AG (CRSP) Stock Moves -1.21%: What You Should Know

      CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $49.89, moving 1.21% from the previous trading session.

      Oct 22Yahoo FinanceCRSP
      Crispr Therapeutics AG (CRSP) Receives a Rating Update from a Top Analyst

      Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

      Oct 22The Globe and MailCRSP
      Brokers Suggest Investing in CRISPR Therapeutics (CRSP): Read This Before Placing a Bet
      Oct 21Yahoo FinanceCRSP
      CRISPR Therapeutics Announces Chief Financial Officer Transition

      ZUG, Switzerland and BOSTON, Oct. 19, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that its Chief Financial Offic...

      Oct 19Business InsiderCRSP
      CRISPR Therapeutics names A.J. Silver as new CFO
      Oct 19Investing.comCRSP
      Where Will CRISPR Therapeutics Stock Be in 2030? | The Motley Fool

      The company's expertise in gene editing could lead to more breakthroughs.

      Oct 18The Motley FoolCRSP
      Cathie Wood Bought More CRISPR Therapeutics Stock 2 Days in a Row. Here's What She Sees in the Biotech Stock.
      Oct 18Yahoo FinanceCRSP
      CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know
      Oct 16Yahoo FinanceCRSP
      Is CRISPR Therapeutics (CRSP) Undervalued As CASGEVY Hopes Face Market Doubts?
      Oct 14Yahoo FinanceCRSP
      CRISPR Therapeutics (CRSP) Stock Looks Rich On Upcoming CTX310 Trial Data
      Oct 14Yahoo FinanceCRSP

      This is the newest page. Registered accounts read further back.